| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4968 | Suku-33 | Novel potent inhibitor of osteoclastogenesis, suppressing both equilibrative nucleoside transporters and concentrative nucleoside transporters |
|
| DCC4969 | Sul-121 Hydrochloride | Novel inhibitor of airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease (COPD) |
|
| DCC4970 | Sulfacetamide | Antibacterial, inhibiting bacterial folic acid synthesis by competing with para amino benzoic acid |
|
| DCC4971 | Sulfazecin | β-Lactam antibiotic against multi-drug resistant pathogens |
|
| DCC4972 | Sulfonyl Quinoxaline 1 | Novel inhibitor of RhoG-hepcidin uptake |
|
| DCC4973 | Sulfosuccinimidyl Oleate Sodium | Neuroprotective agent, alleviating stroke-induced neuroinflammation |
|
| DCC4974 | Suloctidil Hydrochloride | Peripheral vasodilator |
|
| DCC4975 | Sulukast | Novel, potent, selective, and competitive antagonist of LTD4 and LTE4 |
|
| DCC4976 | Sumanirole | D2 selective dopamine agonist, showing anxiolytic and anti-parkinsonian activities |
|
| DCC4977 | Sun13837 | Novel fibroblast growth factor receptor modulator for treating neurodegenerative diseases |
|
| DCC4978 | Sun-c5174 | 5-HT2 antagonist |
|
| DCC4979 | Supradamal | Potent Inhibitor of Plasmodium FK506 Binding Protein 35 (FKBD35), also act as a HIV inhibitor |
|
| DCC4980 | suvanine | Antagonist of the mammalian bile acid sensor farnesoid-X-receptor (FXR) |
|
| DCC4981 | Sv-293 | Selective D2 dopamine receptor antagonist |
|
| DCC4982 | Sv-iii-130s | D2 dopamine receptor partial agonist in adenylyl cyclase inhibition assay and antagonist in the GIRK and phospho ERK1/2 assays |
|
| DCC4983 | Sw208108 | Novel clickable tumor-specific irreversible inhibitor of stearoyl CoA desaturase (SCD) |
|
| DCC4984 | Swainsonine | Natural potent alpha-mannosidase inhibitor, exhibiting antimetastatic, antiproliferative, and immunomodulatory activities |
|
| DCC4985 | swertisin | Potent differentiating agent |
|
| DCC4986 | S-y048 | Novel selective OXE receptor antagonist |
|
| DCC4987 | Sy-5609 | Novel highly potent and selective CDK7 inhibitor, demonstrating broad anti-tumor activity in vivo |
|
| DCC4988 | Syk-524 | Novel universal opioid receptor agonist |
|
| DCC4989 | Syk-in-ii | Novel inhibitor of the Syk kinase (spleen tyrosine kinase) |
|
| DCC4990 | Syn-1 Peptide | Novel potent and specific inhibitor of syncytin-mediated cell fusion, completely blocking cell fusion at 1.6 μg/ml |
|
| DCC4991 | Syn-1 Scr Peptide | Negative control of Syn-1 peptide, having the same amino acid composition as Syn-1 peptide, but a scrambled sequence |
|
| DCC4992 | syn22269076 | Novel Mycobacterium tuberculosis growth inhibitor |
|
| DCC4993 | Synstab A | Novel microtubule-stablizer |
|
| DCC4994 | Synthalin Dihydrochloride | K+ channel blocker |
|
| DCC4996 | Szv558 | Potent inhibitor of both rodent and human MAO-B, proved to be safe in high doses with no hERG and mutagenic activities and demonstrated neuroprotection in an in vivo chronic model of PD |
|
| DCC4997 | T0511-4424 | Novel COX-2 inhibitor |
|
| DCC4998 | T-0632 | Potent and selective CCKA receptor antagonist |
|
